Publications

• Macrocyclic Peptide Probes for Immunomodulatory Protein CD59: Potent Modulators of Bacterial Toxin Activity and Antibody-Dependent Cytotoxicity
  Angewandte Chemie Int. Ed., 2025, 64 (27), e202422673
  J. K. Bickel, A. I. S. Ahmed, A. B. Pidd, R. M. Morgan, T. E. McAllister, S. Horrell, E. C. Couves, H. Nagaraj, E. J. Bartlett, K. El Omari, A. Kawamura, D. Bubeck*, E. W. Tate*;
• Efficient synthesis of O-glycosylated amino acids
  RSC Chemial Biology 2025,6, 851-856
  F. J. Frank, R. A. Lawson, T. E. McAllister*
• Selective targeting of human TET1 by cyclic peptide inhibitors: Insights from biochemical profiling
  Bioorganic and Medicinal Chemistry 2024, 99, 117597
  K. Šimelis, H. Saraç, E. Salah, K. Nishio, T.E. M^cAllister, T.P. Corner, A. Tumber, R. Belle, C. J. Schofield, H. Suga, A. Kawamura*
• Cyclic peptides target the aromatic cage of a PHD-finger reader domain to modulate epigenetic protein function
  Chemical Science, 2023, 14 (26), 7136-7146
  O. D. Coleman, J. Macdonald, B. Thomson, J. A. Ward, C. J. Stubbs, T. E. McAllister, S. Clark, S. Amin, Y. Cao, M. I. Abboud, Y. Zhang, H. Sanganee, K. V. M. Huber, T. D. W. Claridge,* A. Kawamura*
• Structural diversity in de novo cyclic peptide ligands from genetically encoded library technologies
  Peptide Science 113 (1), e24204
  T. E. M^cAllister*, O. D. Coleman, G. Roper, A. Kawamura*;
• Use of Cyclic Peptides to Induce Crystallization – Case Study with Prolyl Hydroxylase Domain 2
  Scientific Reports 2020, 10(1), 21964.
  R. Chowdhury, M. I. Abboud, T. E. M^CAllister, B. Banerji, B. Bhushan, J. L. Sorensen, A. Kawamura, C. J. Schofield*
• Non-competitive cyclic peptides for targeting enzyme-substrate complexes
  Chemical Science 2018, 9(20), 4569-4578.
  T. E. M^cAllister, T.-L. Yeh, M. I. Abboud, I. K.H. Leung, E. S. Hookway, O. N. F. King, B. Bhushan, S. J. Williams, R. J. Hopkinson, M. Münzel, N. D. Loik, R. Chowdhury, U. Oppermann, T. D. W. Claridge, Y. Goto, H. Suga, C. J. Schofield, A. Kawamura*
• 2-Oxoglutarate regulates binding of hydroxylated hypoxia-inducible factor to prolyl hydroxylase domain 2
  Chemical Communications 2018, 54(25), 3130-3133
  M. I. Abboud, T. E. M^cAllister, I. K. H. Leung, R. Chowdhury, C. Jorgensen, C. Domene, J. Mecinović, K. Lippl, R. L. Hancock, R. J. Hopkinson, A. Kawamura, T. D. W. Claridge, C. J. Schofield*
• KDM4A regulates HIF-1 levels through H3K9me3
  Scientific Reports 2017, 7, 11094
  G. Dobrynin, T. E. M^cAllister, K. B. Leszczynska, S. Ramachandran, A. J. Krieg, A. Kawamura, E. M. Hammond*
• Recent Progress in Histone Demethylase Inhibitors
  Journal of Medicinal Chemistry 2016, 59(4), 1308-1329
  T. E. M^cAllister, K. S. England, R. J. Hopkinson, P. E. Brennan, A. Kawamura,* C. J. Schofield*
• Templating carbohydrate-functionalised polymer-scaffolded dynamic combinatorial libraries with lectins
  Organic & Biomolecular Chemistry 2015, 13(9), 2756-2761
  C. S. Mahon, M. A. Fascione, C. Sakonsinsiri, T. E. M^cAllister, W. B. Turnbull, D. A. Fulton
• A protein‐based pentavalent inhibitor of the cholera toxin B‐subunit
  T. R. Branson, T. E. M^cAllister, J. Garcia-Hartjes, M. A. Fascione, J. F. Ross, T. Wennekes, H. Zuilhof, W. B. Turnbull*
  Angewandte Chemie Int. Ed., 2014, 53 (32), 8323–8327
• Evaluation of the interaction between phosphohistidine analogues and phosphotyrosine binding domains
  ChemBioChem 2014, 15(8), 1088-1091
  T. E. M^cAllister, K. A. Horner, M. E. Webb*
• Prospects for stable analogues of phosphohistidine
  Biochemical Society Transactions 2013, 41(4), 1072-1077
  T. E. M^cAllister, J. J. Hollins, M. E. Webb*
• Triazole phosphohistidine analogues compatible with the Fmoc-strategy
  Organic & Biomolecular Chemistry 2012, 10, 4043-4049.
  T. E. M^cAllister, M. E. Webb*
• Fmoc-chemistry of a stable phosphohistidine analogue
  Chemical Communications 2011, 47(4)
  T. E. M^cAllister, M. G. Nix, M. E. Webb*
  

Links

Google Scholar
Newcastle University staff page